Bioequivalence Study of Two 10 mg Montelukast Immediate-Release Tablets Formulations: A Randomized, Single-Dose, Open-Label, Two Periods, Crossover Study

Enrique Muñoz*, Daniel Horacio Ocampo, Edgar Emilio Espinal and Natalia Yépes

CECIF (Centro de la ciencia y la investigación farmacéutica), Medellín, Colombia

Abstract

A bioequivalence study was developed to compare the bioavailability of two formulations of Montelukast 10 mg tablets in twenty-four healthy volunteers. The Test product was Montelukast® (Montelukast) made by Merck Sharp & Dohme Ltd. (Northumberland - United Kingdom). A crossover design 2 x 2 of single-dose, with two treatments, two periods, two sequences and with a washout period of one week was used. Blood samples were collected from 0, 5 to 24 hours after dosing. The determination of Montelukast in plasma was performed using a previously validated bio-analytical method of high-performance liquid chromatography with fluorescence detector (HPLC-FLD). Through Montelukast concentration curves versus time measured in the volunteers’ plasma, the pharmacokinetic parameters and bioequivalence were determined for both products. The pharmacokinetic parameters determined in this study for both the reference and test products were Cmax 440.6 ± 227.4 ng/ml, 460.5 ± 170.9 ng/ml; AUC0→24 3196.5 ± 1546.8 ng.h/ml, 3284.9 ± 1270.0 ng.h/ml and AUC0→∞ 3162.5 ± 1537.6 ng.h.ml, 3251.6 ± 1221.8 ng.h.ml respectively. For Montelukast, with a confidence interval of 90%, the ratio of the logarithmic transformation test product / reference product for AUC0→∞ was from 94.5 to 110.9 and the ratio test product/reference product for Cmax was from 89.0 to 110.4. These intervals are within the established bioequivalence range and therefore determined that the test formulation is interchangeable or bioequivalent to the reference.

Keywords: Montelukast; Bioequivalence; Pharmacokinetics; High-resolution Liquid chromatography; Spectrophotometry; Fluorescence

Introduction

Montelukast sodium is a hygroscopic; optically active; photolabile; white-colored (or whitish) powder with the following chemical formula: C35H33ClN2NaO4S [1,2] (Figure 1). It is a potent; orally active compound with anti-inflammatory properties that significantly improves asthmatic inflammation parameters. It binds with great affinity and selectivity to CysLT1 receptors over other pharmacologically important receptors of the respiratory tract; such as the prostanoid; cholinergic; or β-adrenergic receptors. Montelukast potently inhibits physiological receptors of the respiratory tract; such as the prostanoid; cholinergic; or β-adrenergic receptors. Montelukast potently inhibits physiological actions of LTC4; LTD4; LTE4 leukotrienes at CysLT1 receptors without any agonist activity [3-5]. Therefore; it is indicated for the prophylaxis and chronic treatment of asthma in adults and 12-month-old or older pediatric patients; and it helps to control the symptoms of seasonal and perennial allergic rhinitis [3].

Montelukast is rapidly absorbed following oral administration; reaching peak plasma concentration of approximately 500 ng/ml between 3 to 4 hours after administering a 10 mg tablet to adults in fasted state. The average oral bioavailability is 64% and is not modified by a standard meal, in addition, the Cmax remains unaffected. Over 99% of Montelukast binds to plasma proteins is extensively metabolized in to undetectable metabolites when plasma concentrations are at steady state. The average plasma clearance of Montelukast in healthy adults is 45 ml/min and it is almost exclusively by biliary route. [3-5]. A half-life between 3.5 and 5.0 hours has been reported for a 10 mg tablet of Montelukast [6-10].

The objective of this study was to establish the Bioequivalence of two Montelukast formulations; comparing the Bioavailability of a single dose of Montelukast 10 mg tablets produced by Tecnoquimicas S.A. (Test Product) to a single dose of Singularair® 10 mg tablets produced by Merck Sharp & Dohme Ltd. (Reference Product).

Product analysis

For the test product; Montelukast 10 mg immediate-release coated tablets; batches 2J2389A; 2R3789A and 2E1775 were used. These were produced by Tecnoquimicas S.A (Jamundi - Colombia). For the reference product; Singularair® 10 mg immediate-release coated tablets; batch H011579 was used; it was produced by Merck Sharp & Dohme Ltd. (Northumberland - United Kingdom). A crossover design 2 x 2 of single-dose, with two treatments, two periods, two sequences and with a washout period of one week was used. Blood samples were collected from 0, 5 to 24 hours after dosing. The determination of Montelukast in plasma was performed using a previously validated bio-analytical method of high-performance liquid chromatography with fluorescence detector (HPLC-FLD). Through Montelukast concentration curves versus time measured in the volunteers’ plasma, the pharmacokinetic parameters and bioequivalence were determined for both products. The pharmacokinetic parameters determined in this study for both the reference and test products were Cmax 440.6 ± 227.4 ng/ml, 460.5 ± 170.9 ng/ml; AUC0→24 3196.5 ± 1546.8 ng.h/ml, 3284.9 ± 1270.0 ng.h/ml and AUC0→∞ 3162.5 ± 1537.6 ng.h.ml, 3251.6 ± 1221.8 ng.h.ml respectively. For Montelukast, with a confidence interval of 90%, the ratio of the logarithmic transformation test product / reference product for AUC0→∞ was from 94.5 to 110.9 and the ratio test product/reference product for Cmax was from 89.0 to 110.4. These intervals are within the established bioequivalence range and therefore determined that the test formulation is interchangeable or bioequivalent to the reference.

Figure 1: Sodium Montelukast. [R-(E)]-1-[[1-[3-[2-(7-chloro-2-quinolinyl) ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl] cyclop propaneacetic acid; monosodium salt. Taken from DrugBank [6].

*Corresponding author: Enrique Muñoz Carnago, CECIF (Centro de la Ciencia y la investigación Farmacéutica), Medellín, Antioquia, Colombia, Tel: 57-4-3778584 ext. 107/104; Fax: 57-4-3778584 ext. 102; E-mail: estudiosbiofarmaceuticos@cecf.org

Received May 02, 2014; Accepted May 25, 2014; Published May 31, 2014


Copyright: © 2014 Muñoz E, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Prior to the Bioequivalence study development; both products were compared regarding pharmaceutical forms; labeling; patient information leaflet and tablet description. The assessment of the active ingredient identity, the active ingredient content, the uniformity of dosage units, the dissolution test and dissolution profiles in four different media were also performed using analytical methods, based on a monograph from the British pharmacopoeia; proposed for publishing in 2014; and the FDA guidelines [11,12]; all of this in order to determine the pharmaceutical equivalence of the Test and Reference products.

Products would be accepted as pharmaceutical bioequivalents and appropriate for the bioequivalence study, if, the retention time of Montelukast (test sample) and the standard (reference) by active ingredient identity analysis is identical; if, the % assay and content uniformity of the products show 95.0 and 105.0% of the declared amount; if, in dissolution testing, the dissolved percentage of the product is not less than 80% in 20 min; if, the dissolution profile values of % “point-to-point differences” between 0 and 15 and %2 similar factor” between 50 and 100, besides coefficients of variation for dissolved Montelukast with a maximum of 20% on the first time point (mention minutes here) and under 10% for the remaining time points (mention minutes) [11,12].

Subjects and Methods

Subjects

Volunteers were enrolled through open announcement made by the CECIF in different universities throughout the region; and through online announcement in the website: www.cecifcolombia.org and through informative talks about the study. Subjects were healthy Colombians of both genders; aged between 18 and 55 years old. Subjects had a weight difference limit of 15% according to their height and a body mass index between 20 and 25 Kg/m2 [13].

Subject’s inclusion in the study was assessed for those volunteers with no history of liver; heart; kidney; central nervous system or respiratory disease. Normal blood pressure (for adults; systolic pressure must be under 120 - 130 mmHg and 80 - 90 mmHg for diastolic pressure); appropriate heart rate (normal resting rate is between 60 and 100 pulsations per minute) and normal spirometry. Normal results based on performed clinical exams (complete blood count; fasting blood glucose; aminotransferase analysis; full cholesterol panel test; serum creatinine; serum triglycerides; HIV test; serum albumin; urine cytology) and a negative pregnancy test for female volunteers.

Volunteers were informed about the study nature and a written consent form was obtained from each subject. They were asked not to take any medication; enzymatic inducers and even contraceptives for at least two weeks prior to the first sample collection period [14-16]; to avoid the intake of food or beverages containing xanthine; chocolates; tea; coffee and cola based beverages; and not to consume alcoholic beverages and cigarettes 48 hours before the dose administration. Volunteers had a 12 hour fasting before administering the Montelukast 10 mg tablet and were allowed to have breakfast only after 2 and a half hours after dose administration.

Study design

Study protocol and consent form were approved by the Bioethics Committee of Universidad de Antioquia’s Research Headquarters CBE-SIU in Medellin; Colombia; which is regulated by resolution 008430 from October 4th; 1993 from the Colombian Ministry of Health; which establishes the technical; scientific and management regulations for health research and complies with guidelines of resolution 002378 from June 25th; 2008 from the Ministry of Health and Social Protection; which establishes the Good Clinical Practices for institutions conducting drug research with human subjects. It also adjusts to the principles of the World Medical Association presented in the Declaration of Helsinki (1964); last review in 2013 and the Code of Federal Regulations; title 45; part 46; regarding the protection of human subjects; from the United States Department of Health & Human Services of the National Institutes of Health (June 18th; 1991) [17-20].

This was a crossover 2 x 2 randomized; single-dosed; two treatments; two periods; two sequences; with an appropriate one-week washout period study. Each subject was randomly assigned to a treatment sequence and all subjects took both the Montelukast Test Product and the Reference Product.

Drug administration

For samples collection; volunteers were gathered for more than 12 hours in a space that belongs to the Corporation for Health Studies; CES Clinic (Medellin - Colombia). They were subjected to identical housing environments such as food intake; liquid volume intake; physical activity; lying position; among others. One hour before dose administration; an IV catheter was introduced to each volunteer and a target blood sample was collected. The dose was administered orally with 240 ml of water.

Sampling

Blood samples were collected from each volunteer’s antecubital vein using test tubes with anticoagulant (Heparin sodium); according to the following timepoints: 0; 0.5; 1; 1.5; 2; 2.5; 3; 3.5; 4; 6; 8; 12 and 24 hours. In an approximate time range of 20 min after collecting the samples; the tubes were centrifuged at 3500 rpm to obtain blood plasma; which was stored in covered sterile tubes in order to provide ultraviolet protection given the high photosensitivity of Montelukast; and they were dropped immediately to -20°C until analysis [21,22].

During both study periods; volunteers were under medical care with constant vital signs monitoring to prevent or counteract any adverse reaction.

Plasma samples analyses

Plasma concentrations of Montelukast were measured through a bio-analytical method using High-Performance Liquid Chromatography (HPLC) previously validated by the CECIF following the established guidance from international analytic method validation guidelines to demonstrate an adequate sensitivity; specificity; linearity; accuracy and precision [23-25].

Extraction conditions of Montelukast from plasma and chromatographic conditions for its quantification were determined during the prior review of what is reported on literature; making the required modifications to optimize the process [7,8,10,21,26-28].

Samples preparation was made through protein precipitation with acetonitrile and their analysis was made by using a Liquid Chromatograph with Fluorescence Detection (FLD). For this case; a Shimadzu UFLC-NEXERA system was used. Data acquisition was performed using LabSolutions 2008-2010 software by Shimadzu Corporation. Analyte separation was achieved with a Zorbax Eclipse...
XDB-C18 4.6 mm ID × 150 mm (5 μm) chromatographic column at 40°C. An isocratic elution with a mobile phase composed of acetonitrile: trihydrate sodium acetate buffer 25 mM at pH = 4.0; 75:25; with a constant flow of 1 ml/min was done. Total runtime was 10 min. Montelukast was monitored at an emission wavelength of 350 nm and a 390 nm excitation wavelength; and 25 μl were injected into the HPLC.

**Pharmacokinetic parameters analysis**

Montelukast plasma levels for each of the volunteers in each timepoint were tabulated and according to this data; Montelukast plasma concentration vs. time curves were drawn for both formulations. Pharmacokinetic parameters compared in this Bioequivalence single-dose study for both formulations are as follows: $C_{\text{max}}$ and $T_{\text{max}}$ which correspond to the curve peak; $\text{AUC}_0^{\infty}$ calculated with the trapezoidal rule; area under the curve since the last sampling timepoint ($t$) to infinity ($\text{AUC}_0^{\infty}$) determined through equation $\text{AUC}_0^{\infty} = C_{\text{max}}/K_e$; $\text{AUC}_0^t$; $\text{AUC}_0^{T_{1/2}}$; $\text{AUC}_0^{t_{1/2}}$; $t_{1/2}$; $\text{AUC}_0^{24}$; $\text{AUC}_0^{24-\text{t}_{1/2}}$. It was concluded that both formulations are bioequivalents, if the CI of 90% is within the bioequivalence range established by the FDA [29].

The statistical method used to determine the Bioequivalence between both formulations was based on the procedure known as two one-sided test; to determine if transformed average values of pharmacokinetic parameters measured after administering both the test and reference products are comparable [29].

For the statistical analysis of data derived from this in vivo study; general parametric procedures for linear models (normal theory) were used and an analysis of variance (ANOVA) was performed using the statistical application Phoenix™ Winnonlin®; version 6.3; 2013; based on the pharmacokinetic parameters $C_{\text{max}}$ and $\text{lnAUC}_0^{\infty}$; keeping the average concentration profiles of volunteers grouped in categories. Some sources of variation such as cycles and treatments were also included, as established by the FDA bioequivalence division [30].

Results

**Products analysis**

Comparison of pharmacological forms, labeling, patient information leaflet and the tablets did not show any significant difference between two products. The active ingredient identity analysis showed identical behavior between the reference drug and the test drug were observed. They showed minor point-to-point difference and profile similarity, complying with difference and similarity factors $f_1$ and $f_2$.

**Subjects**

For the study; selected subjects were healthy Colombians of both genders; aged between 18 and 30 years old. Average weight and height were 62.70 ± 10.15 kg and 1.68 ± 0.07 m respectively. No severe adverse event that inhibited the participation of any of the subjects was observed during the conduction of the study.

Two female volunteers did not show up for the study due to personal issues; so two male volunteers were retired to keep pair sequences and complete statistical treatment; without affecting the final result after having performed the corresponding randomization test. Thus; the study was performed on twenty subjects.

**Bio-analytic method validation**

The method was selective, during the analysis of six target plasma samples from different sources, plus a hemolyzed sample and a lipid sample, no interferences were found between the analyte and matrix’s endogenous components. Calibration curve for Montelukast in plasma showed linearity in a concentration range from 10 to 1000 ng/ml with a correlation coefficient of 1.0. Detection limit for the study was 1.1 ng/ml and quantification limit was 1.9 ng/ml. Accuracy expressed in intra-day coefficients of variation was 1.1%; 1.7% and 1.6% for 50 ng/ml; 250 ng/ml and 750 ng/ml respectively; and inter-day coefficient was 2.9%; 1.0% and 1.0% for 50 ng/ml; 250 ng/ml and 750 ng/ml respectively. As for the method’s retrieval; 87.9%; 94.7% and 97.5% were obtained for 50 ng/ml; 250 ng/ml and 750 ng/ml respectively. Montelukast proved its stability against the different conditions proposed by the FDA [24].

**Pharmacokinetic and statistical analysis**

The average of the pharmacokinetic profiles and Montelukast concentration in plasma vs. time for all 20 volunteers is shown on Figure 2; and the average pharmacokinetic parameters are described in Table 2.

ANOVA results showed there are no significant statistical differences regarding the following variables: cycles and treatment in terms of $C_{\text{max}}$ and $\text{AUC}_0^{\infty}$.

With a CI of 90%, the average of the $C_{\text{max}}$ and $\text{AUC}_0^{\infty}$ ratio between the test and reference products for all 20 volunteers is shown on Table 3.

**Discussion**

Twenty volunteers completed the study; none of them showed adverse reactions. Sample size was chosen following the Instituto Nacional de Vigilancia de Medicamentos y Alimentos (INVIMA)
Table 3: Confidence Intervals of 90% and average of the ratio Cmax between the Test product and the Reference products of 10 mg Montelukast tablets.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Test Product CI 90%</th>
<th>Reference Product CI 90%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cmax (ng/ml)</td>
<td>110.4-122.8</td>
<td>110.4-122.8</td>
</tr>
<tr>
<td>AUC∞ (ng/h.ml)</td>
<td>3196.5-3196.5</td>
<td>3196.5-3196.5</td>
</tr>
<tr>
<td>Ke (h⁻¹)</td>
<td>0.203 ± 0.163</td>
<td>0.203 ± 0.163</td>
</tr>
<tr>
<td>t½ (h)</td>
<td>3.4 ± 1.6</td>
<td>3.4 ± 1.6</td>
</tr>
</tbody>
</table>

Table 2: Average of the pharmacokinetic parameters of Montelukast tablets after a 10 mg single-dose administration of the test product and the reference product to 20 volunteers.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Ratio Test Product/Reference Product CI 90%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cmax (ng/ml)</td>
<td>99.7</td>
</tr>
<tr>
<td>lnAUC∞ (ng.h/ml)</td>
<td>102.4</td>
</tr>
</tbody>
</table>

As for the bioequivalence of both formulations, Table 3 shows, for a CI of 90%, that the ratio between the test and reference products of Cmax and AUC∞ falls within the bioequivalence range of 80 to 125 established by the FDA [30]. Therefore, it can be concluded that the test formulation (10 mg Montelukast coated tablets) produced by Tecnoquimicas S.A.; is interchangeable or bioequivalent to the reference formulation (Singulair® 10 mg coated tablets) produced by Merck Sharp & Dohme Ltd.

Acknowledgements

This study was sponsored by TECNOQUIMICAS S.A.

We thank the investigators group from the medical division at Tecnoquimicas S.A. for enabling the development of this project; which is required to register the product before the INVIMA or any other Regulatory Agencies.

Let this be the record that there are no conflicting interests neither between the two institutions nor their investigators.

References


Submit your next manuscript and get advantages of OMICS Group submissions

Unique features:
• User friendly/feasible website-translation of your paper to 50 world’s leading languages
• Audio Version of published paper
• Digital articles to share and explore

Special features:
• 350 Open Access Journals
• 30,000 editorial team
• 21 days rapid review process
• Quality and quick editorial, review and publication processing
• Indexing in PubMed (partial), Scopus, EBSCO, Index Copernicus and Google Scholar etc
• Sharing Option: Social Networking Enabled
• Authors, Reviewers and Editors rewarded with online Scientific Credits
• Better discount for your subsequent articles

Submit your manuscript at: https://www.editorialmanager.com/jbiobio